"Groupthink" Leads Big Pharma To Downplay Neurosciences At Industry's Peril
Executive Summary
A generation of potentially useful drugs for neurologic disorders may be lost if something isn't done to shore up early stage companies being "strangled fiscally" by the shift in partnering and financing toward later-stage projects, says Harry Tracy, president of NI Research
You may also be interested in...
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them
Biovail Walks The Walk: More CNS Licensing, Acquisitions Planned For 2010
Biovail is putting its money where its mouth is. The Toronto-based specialty pharma announced plans early in 2008 to turn itself into a specialty central nervous system company, and - after five deals in 18 months -Biovail execs are more excited than ever about the opportunities open to them
CytRx Gets FDA Go-Ahead To Study Stalled ALS Drug Under Revised Protocol
CytRx, which has bet heavily on oncology since FDA put a hold on the CNS drug, plans to resume partnering talks for arimoclomol as it restarts the trial.